Chronic pain patients using a 60-day implantable nerve stimulator are about to find their device sold by one of the world’s largest medical-device companies. Medtronic announced on 20 May 2026 its intent to acquire SPR Therapeutics, the maker of the Sprint Peripheral Nerve Stimulation System, for approximately $650 million in upfront cash. The deal makes SPR the second peripheral nerve stimulation specialist bought by a top-three neuromodulation incumbent in seven months, after Boston Scientific’s $533 million acquisition of Nalu Medical, which was announced in October 2025 and closed in January 2026.
The deal
Medtronic is paying approximately $650 million in upfront cash for all outstanding equity in SPR Therapeutics. The transaction is expected to close within the first half of Medtronic’s fiscal year 2027, which began on 25 April 2026. The announcement landed on the same day as Medtronic’s Q4 FY26 earnings release (20 May 2026, pre-market), placing the SPR deal inside the same news window as the company’s full-year results commentary. Medtronic’s Pain Therapies business sits within its broader Neuromodulation portfolio, which already includes Intellis spinal cord stimulation, the InterStim sacral neuromodulation system for overactive bladder and faecal incontinence, and the recently FDA-approved Altaviva implantable tibial neuromodulation device.
What Sprint does
SPR’s Sprint Peripheral Nerve Stimulation System is an FDA-cleared, temporary 60-day percutaneous nerve stimulation therapy for chronic pain. The system uses a small lead inserted percutaneously near a target peripheral nerve, with an external pulse generator delivering stimulation over the 60-day treatment window. The lead is then removed; no permanent implant remains. The largest retrospective real-world dataset on Sprint covers more than 6,100 patients, with 71% reporting meaningful pain relief or quality-of-life improvement following the 60-day therapy. The temporary, non-implanted nature of the system positions it adjacent to pharmacological pain management rather than as a direct competitor to permanent implantable neuromodulation devices.
The second PNS rollup in seven months
Medtronic’s move follows Boston Scientific’s October 2025 agreement to acquire Nalu Medical, which closed for $533 million in January 2026. Nalu’s neuromodulation system is a different PNS architecture from Sprint. Nalu uses a permanent peripheral nerve stimulation implant with an external wearable activator, while Sprint is a temporary lead removed after 60 days. The strategic logic of the two deals is nonetheless the same. Two of the three largest neuromodulation incumbents have now backfilled their pain portfolios with PNS specialists rather than build the category internally.
Pain management is a high-volume, large-addressable-market indication that strategic incumbents want exposure to without the multi-year build cycle and clinical risk of de novo product development. PNS specialists like SPR and Nalu had reached FDA clearance, commercial uptake, and meaningful real-world evidence on a scale that made acquisition cleaner than partnership or build-from-zero. The third top-three incumbent, Abbott, has not yet made a comparable PNS acquisition but holds substantial existing pain franchises through Proclaim XR and Proclaim Plus spinal cord stimulation and the Proclaim DRG system. Its absence from the M&A pattern is now a watch item.
What this resets for the pre-IPO neuromod cohort
The Medtronic-SPR deal lands in the same week as the Mobia Medical IPO underperformance and the BlueWind Medical $47.8 million round. The combined picture for VC-backed bioelectronic-medicine companies preparing exits is now clearer than it has been at any point this year. Public capital markets are compressing on first-listing prints (MOBI -22% in week one). Private capital is still available (BlueWind $47.8 million on 14 May). Strategic M&A by top-three incumbents is active and pricing at premium upfront cash multiples ($650 million for SPR; $533 million for Nalu).
The cleanest exit for the next wave of bioelectronic-medicine companies (SetPoint, Salvia BioElectronics, Nervonik, Spark Biomedical) may be a strategic buyer rather than a public listing. Abbott is now the most-watched buyer in the absence of a comparable PNS deal. The next vagus nerve stimulation transaction (SetPoint is the most-watched candidate) will indicate whether the consolidation logic extends from PNS into the broader bioelectronic medicine map.
What to watch
The first signal is Abbott’s response. Abbott’s pain franchise overlap with both Medtronic and Boston Scientific is meaningful, and continued silence on PNS through the next two quarters would itself be a strategic statement. The second signal is the SetPoint financing pipeline. SetPoint is the most-watched VNS-for-inflammation private company and the natural test case for whether the consolidation logic extends from PNS into vagus nerve stimulation broadly. The third signal is regulatory: any FDA action that changes the reimbursement or coding pathway for PNS would alter the deal economics on both Sprint and Nalu.
The broader bioelectronic-medicine commercial inflection Inside BCI tracked on 5 May now has a second layer above it: the strategic-buyer endgame. Both layers are real, and they are moving on different timelines from the same underlying clinical and commercial momentum.
Sources
- Medtronic announces intent to acquire SPR Therapeutics, Inc. (Medtronic Newsroom, 20 May 2026)
- Medtronic to Grow Chronic Pain Portfolio with $650M SPR Therapeutics Buy (ODT Magazine)
- Medtronic to acquire peripheral nerve stim developer SPR Therapeutics (MassDevice)
- Medtronic plans $650M SPR Therapeutics acquisition (StockTitan)
- Boston Scientific Announces Agreement to Acquire Nalu Medical (Boston Scientific Newsroom, 17 October 2025)
- Boston Scientific completes Nalu Medical acquisition (MassDevice)
- Proclaim XR & Proclaim Plus SCS Systems (Abbott Neuromodulation)